Sandler Alan B. sold $1.3M of RVMD
Sandler Alan B. (Chief Development Officer) sold 6,309 shares of Revolution Medicines, Inc. (RVMD) at an average of $202.14 ($200.82–$204.72, $1.28M total) across 5 trades on 2026-09-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The insider sale is a material event for RVMD, likely generating short‑term pressure but not altering long‑term fundamentals.
Market read
First‑report insider sale of $1.3 M, modest impact on RVMD price.
What to watch
Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.
Background
Form 4 filings are primary disclosures; this sale is the first public report of the transaction.
Ticker impact
Chief Development Officer Sandler Alan B. sold $1.3M of RVMD shares via a 10b5‑1 plan, reducing his stake to 52,559 shares.
likely slight downward pressure as the market prices the insider sell
A C-level insider sold over 6,300 shares at $200‑$205 each, a material amount for a mid‑cap biotech, and such sales often trigger short‑term sell‑offs.
Market effects
May prompt modest re‑rating of biotech insider activity risk.
Limited to U.S. biotech investors.
Low; impact confined to RVMD shareholders.
Counterpoint
The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.
Key entities
- companyRevolution Medicines, Inc.
Biotech firm developing oncology therapies, ticker RVMD.
- personAlan B. Sandler
Chief Development Officer of Revolution Medicines.
